Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry Anderson, Muhamed Baljević, Rachid Baz, Erica Campagnaro, C. L. Costello, Christopher R. D’Angelo, Benjamin A. Derman, Srinivas Devarakonda, Noura Elsedawy, Amandeep Godara, Kelly Godby, J Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Hans Chulhee Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy J. Robinson, Aaron Rosenberg, Shayna Sarosiek, Mark A. Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Varshavsky‐Yanovsky, Dan T. Vogl, J Christine Ye, Emily Kovach, Rashmi Kumar
The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).